The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Jens Nørkær Sørensen - One of the best experts on this subject based on the ideXlab platform.
-
repeatability of Tumor Blood Flow quantification with 82 rubidium pet ct in prostate cancer a test retest study
EJNMMI research, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Katrine Bodkergaard Nielsen, Jens Nørkær SørensenAbstract:Non-invasive Tumor Blood Flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. Validation data have recently been published on prostate TBF measurement with the widely used positron emission tomography (PET) Flow tracer 82Rubidium (82Rb). However, no test-retest data is available for TBF measurement with 82Rb PET in prostate cancer. Such information is important to determine the potential clinical usefulness of the technique. The aim of the present study was to determine the test-retest repeatability of TBF measurement with both dynamic and static 82Rb PET. We recruited 10 low-to-high-risk prostate cancer patients scheduled for clinical prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) or magnetic resonance imaging. Pelvic and cardiac static and dynamic 82Rb PET/CT were performed at baseline and repeated on a different day within 1 week. In total, 11 primary lesions were analyzed. For K1, standardized uptake values (SUV)max, SUVmean, and SUVpeak, prostate cancer 82Rb PET TBF has a repeatability of 32%, 51%, 53%, and 58% and an intraclass correlation of 0.98, 0.89, 0.88, and 0.88, respectively. Dynamic 82Rb PET/CT with kinetic modeling measures TBF in prostate cancer with high repeatability, which allows identification of Blood Flow changes of 32%. Static late-uptake 82Rb PET/CT is inferior, and only intra-individual Blood Flow changes above 51% can hence be recognized.
-
Test-retest study of Tumor Blood Flow quantification with 82Rubidium-PET/CT in prostate cancer
The Journal of Nuclear Medicine, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Jens Nørkær Sørensen, Lars Poulsen TolbodAbstract:1556 Objectives: Non-invasive quantification of Tumor Blood Flow (TBF) is a potential method for risk-stratification and monitoring in prostate cancer. We have recently validated 82Rubidium (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer. However, no test-retest data exist on prostate TBF measurement with 82Rb PET. This information is crucial to determine the potential clinical impact of this method. The aim of this study was to determine the reproducibility of 82Rb PET for TBF measurement. Methods: Ten low-risk to high-risk prostate cancer patients were recruited in connection with clinical prostate specific membrane antigen (PSMA) PET/ computed tomography (CT) or magnetic resonance imaging (MRI). Static 82Rb PET/CT scans were performed of the pelvic region and retest scans were performed on a different day, within one week of the baseline scan. Since the variance of the differences depend on the mean, the analyses were performed on log-transformed data to avoid this bias. Results: TBF with 82Rb PET can be measured in prostate Tumors with an intraclass correlation of (0.89; 0.88 and 0,88); a within-subject coefficient of variance of (18.3 %; 18.9 % and 21.0 %); and a repeatability coefficient of (50.8 %; 52.3 % and 58.3 %) for SUVmax, SUVmean and SUVpeak respectively. Conclusions: TBF measured using static 82Rb PET/CT in prostate cancer can be reproduced with a coefficient of variance and repeatability of approximately 20% and 55%, respectively, depending on SUV measure. Consequently, the method can be applied to monitor relative changes in TBF above 55% in serial exams. Financial support This work was financially supported by The Danish Cancer Society, Health Research Fund of Central Denmark Region, P. Carl Petersens Fond, Dansk Kraeftforskningsfond and Knud og Edith Eriksens Mindefond.
-
test retest study of Tumor Blood Flow quantification with 82rubidium pet ct in prostate cancer
The Journal of Nuclear Medicine, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Jens Nørkær SørensenAbstract:1556 Objectives: Non-invasive quantification of Tumor Blood Flow (TBF) is a potential method for risk-stratification and monitoring in prostate cancer. We have recently validated 82Rubidium (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer. However, no test-retest data exist on prostate TBF measurement with 82Rb PET. This information is crucial to determine the potential clinical impact of this method. The aim of this study was to determine the reproducibility of 82Rb PET for TBF measurement. Methods: Ten low-risk to high-risk prostate cancer patients were recruited in connection with clinical prostate specific membrane antigen (PSMA) PET/ computed tomography (CT) or magnetic resonance imaging (MRI). Static 82Rb PET/CT scans were performed of the pelvic region and retest scans were performed on a different day, within one week of the baseline scan. Since the variance of the differences depend on the mean, the analyses were performed on log-transformed data to avoid this bias. Results: TBF with 82Rb PET can be measured in prostate Tumors with an intraclass correlation of (0.89; 0.88 and 0,88); a within-subject coefficient of variance of (18.3 %; 18.9 % and 21.0 %); and a repeatability coefficient of (50.8 %; 52.3 % and 58.3 %) for SUVmax, SUVmean and SUVpeak respectively. Conclusions: TBF measured using static 82Rb PET/CT in prostate cancer can be reproduced with a coefficient of variance and repeatability of approximately 20% and 55%, respectively, depending on SUV measure. Consequently, the method can be applied to monitor relative changes in TBF above 55% in serial exams. Financial support This work was financially supported by The Danish Cancer Society, Health Research Fund of Central Denmark Region, P. Carl Petersens Fond, Dansk Kraeftforskningsfond and Knud og Edith Eriksens Mindefond.
Jeffrey L. Evelhoch - One of the best experts on this subject based on the ideXlab platform.
-
Measurement of relative regional Tumor Blood Flow in mice by deuterium NMR imaging.
Magnetic resonance in medicine, 1992Co-Authors: Jeffrey L. Evelhoch, Jacqueline B. Larcombe Mcdouall, James Mattiello, Nicholas E. SimpsonAbstract:A noninvasive method to measure relative regional Tumor Blood Flow (rTBF) throughout murine Tumors which uses deuterium NMR imaging to observe regional uptake of HOD after bolus iv injection of D2O is introduced. HOD uptake images are formed by subtraction of a background (preinjection) image from 94-s gradient-refocused deuterium NMR images acquired starting 30 s and 10 min after D2O injection. The pixel intensity in the HOD uptake image acquired starting 30 s after injection is directly related to rTBF with a limit of detection estimated at 7 ml/(100 g-min). The image acquired 10 min after D2O injection extends the estimated limit of detection for rTBF to 3 ml/(100 g-min). Heterogeneity in rTBF and regional effects of photodynamic therapy within RIF-1 Tumors are readily perceived. This method may provide a valuable tool to further our understanding of the relationship between Blood Flow and therapeutic response in Tumors. © 1992 Academic Press, Inc.
-
Measurement of Tumor Blood Flow by deuterium NMR and the effects of modifiers.
NMR in biomedicine, 1992Co-Authors: Jeffrey L. EvelhochAbstract:Tumor metabolism is directly coupled to Tumor Blood Flow (TBF) and both metabolism and Blood Flow may be determinants of Tumor response to treatment. Since NMR has been used extensively to monitor Tumor metabolism noninvasively, development of NMR-based methods for TBF measurement was motivated by the desire to examine the roles Tumor metabolism and Blood Flow may play as determinants of therapeutic response. The concept of using deuterated water as an NMR-detectable, Flow-limited tracer for the measurement of tissue Blood Flow (or capillary perfusion) was introduced in 1987 by Ackerman and coworkers (Proc. Natl., Acad. Sci., USA 84, 4099-4102 (1987)). Since that time, methods have been devised using both spectroscopic and imaging detection for TBF measurement based on either clearance or uptake of deuterated water. In general, the clearance methods are more straightforward to implement, while the uptake methods are less invasive to the Tumor. When used with appropriate caution, both approaches yield reliable results. To date, these methods have been applied in a relatively limited number of animal Tumors. However, their use is increasing and some of these methods ultimately should be applicable in human Tumors.
-
Relative volume-average murine Tumor Blood Flow measurement via deuterium nuclear magnetic resonance spectroscopy.
Magnetic resonance in medicine, 1991Co-Authors: James Mattiello, Jeffrey L. EvelhochAbstract:A deuterium NMR spectroscopic method to determine relative Tumor Blood Flow (TBF) by measuring the increase in Tumor HOD concentration after intravenous injection of 100 μl D2O (0.9% NaCl) is presented. An integration approach analogous to that validated for positron emission tomographic measurement of cerebral Blood Flow was implemented. Computer simulations indicated that integration from 30 to 120 s minimizes the sensitivity of the uptake integral to the shape of the arterial input function, which cannot be assessed in each mouse, while maintaining both a nearly linear relationship between TBF and the integral and high NMR signal-to-noise. A strong positive linear correlation was observed between the uptake integral and TBF measured by D2O clearance in both untreated Tumors (n = 19; P < 0.001) and Tumors after hyperthermia (n = 16; P < 0.001). This method can measure relative TBF in Tumors with heterogeneous Blood Flow and is ideally suited to concurrent or interleaved measurement of TBF and metabolism via multinuclear NMR spectroscopy. © 1991 Academic Press. Inc.
Mads Ryø Jochumsen - One of the best experts on this subject based on the ideXlab platform.
-
repeatability of Tumor Blood Flow quantification with 82 rubidium pet ct in prostate cancer a test retest study
EJNMMI research, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Katrine Bodkergaard Nielsen, Jens Nørkær SørensenAbstract:Non-invasive Tumor Blood Flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. Validation data have recently been published on prostate TBF measurement with the widely used positron emission tomography (PET) Flow tracer 82Rubidium (82Rb). However, no test-retest data is available for TBF measurement with 82Rb PET in prostate cancer. Such information is important to determine the potential clinical usefulness of the technique. The aim of the present study was to determine the test-retest repeatability of TBF measurement with both dynamic and static 82Rb PET. We recruited 10 low-to-high-risk prostate cancer patients scheduled for clinical prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) or magnetic resonance imaging. Pelvic and cardiac static and dynamic 82Rb PET/CT were performed at baseline and repeated on a different day within 1 week. In total, 11 primary lesions were analyzed. For K1, standardized uptake values (SUV)max, SUVmean, and SUVpeak, prostate cancer 82Rb PET TBF has a repeatability of 32%, 51%, 53%, and 58% and an intraclass correlation of 0.98, 0.89, 0.88, and 0.88, respectively. Dynamic 82Rb PET/CT with kinetic modeling measures TBF in prostate cancer with high repeatability, which allows identification of Blood Flow changes of 32%. Static late-uptake 82Rb PET/CT is inferior, and only intra-individual Blood Flow changes above 51% can hence be recognized.
-
Test-retest study of Tumor Blood Flow quantification with 82Rubidium-PET/CT in prostate cancer
The Journal of Nuclear Medicine, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Jens Nørkær Sørensen, Lars Poulsen TolbodAbstract:1556 Objectives: Non-invasive quantification of Tumor Blood Flow (TBF) is a potential method for risk-stratification and monitoring in prostate cancer. We have recently validated 82Rubidium (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer. However, no test-retest data exist on prostate TBF measurement with 82Rb PET. This information is crucial to determine the potential clinical impact of this method. The aim of this study was to determine the reproducibility of 82Rb PET for TBF measurement. Methods: Ten low-risk to high-risk prostate cancer patients were recruited in connection with clinical prostate specific membrane antigen (PSMA) PET/ computed tomography (CT) or magnetic resonance imaging (MRI). Static 82Rb PET/CT scans were performed of the pelvic region and retest scans were performed on a different day, within one week of the baseline scan. Since the variance of the differences depend on the mean, the analyses were performed on log-transformed data to avoid this bias. Results: TBF with 82Rb PET can be measured in prostate Tumors with an intraclass correlation of (0.89; 0.88 and 0,88); a within-subject coefficient of variance of (18.3 %; 18.9 % and 21.0 %); and a repeatability coefficient of (50.8 %; 52.3 % and 58.3 %) for SUVmax, SUVmean and SUVpeak respectively. Conclusions: TBF measured using static 82Rb PET/CT in prostate cancer can be reproduced with a coefficient of variance and repeatability of approximately 20% and 55%, respectively, depending on SUV measure. Consequently, the method can be applied to monitor relative changes in TBF above 55% in serial exams. Financial support This work was financially supported by The Danish Cancer Society, Health Research Fund of Central Denmark Region, P. Carl Petersens Fond, Dansk Kraeftforskningsfond and Knud og Edith Eriksens Mindefond.
-
test retest study of Tumor Blood Flow quantification with 82rubidium pet ct in prostate cancer
The Journal of Nuclear Medicine, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Jens Nørkær SørensenAbstract:1556 Objectives: Non-invasive quantification of Tumor Blood Flow (TBF) is a potential method for risk-stratification and monitoring in prostate cancer. We have recently validated 82Rubidium (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer. However, no test-retest data exist on prostate TBF measurement with 82Rb PET. This information is crucial to determine the potential clinical impact of this method. The aim of this study was to determine the reproducibility of 82Rb PET for TBF measurement. Methods: Ten low-risk to high-risk prostate cancer patients were recruited in connection with clinical prostate specific membrane antigen (PSMA) PET/ computed tomography (CT) or magnetic resonance imaging (MRI). Static 82Rb PET/CT scans were performed of the pelvic region and retest scans were performed on a different day, within one week of the baseline scan. Since the variance of the differences depend on the mean, the analyses were performed on log-transformed data to avoid this bias. Results: TBF with 82Rb PET can be measured in prostate Tumors with an intraclass correlation of (0.89; 0.88 and 0,88); a within-subject coefficient of variance of (18.3 %; 18.9 % and 21.0 %); and a repeatability coefficient of (50.8 %; 52.3 % and 58.3 %) for SUVmax, SUVmean and SUVpeak respectively. Conclusions: TBF measured using static 82Rb PET/CT in prostate cancer can be reproduced with a coefficient of variance and repeatability of approximately 20% and 55%, respectively, depending on SUV measure. Consequently, the method can be applied to monitor relative changes in TBF above 55% in serial exams. Financial support This work was financially supported by The Danish Cancer Society, Health Research Fund of Central Denmark Region, P. Carl Petersens Fond, Dansk Kraeftforskningsfond and Knud og Edith Eriksens Mindefond.
Peter Vaupel - One of the best experts on this subject based on the ideXlab platform.
-
The influence of Tumor Blood Flow and microenvironmental factors on the efficacy of radiation, drugs and localized hyperthermia.
Klinische Padiatrie, 1997Co-Authors: Peter VaupelAbstract:It is generally accepted that Tumor Blood Flow, microcirculation, oxygen and nutrient supply, tissue pH distribution, and the bioenergetic status-factors which are usually closely linked and which define the so-called metabolic microenvironment--can markedly influence the therapeutic response of malignant Tumors to conventional irradiation, chemotherapy, other nonsurgical treatment modalities, and the cell proliferation activity within Tumors. Currently available information on the parameters defining the metabolic micromilieu in human Tumors is presented in this review. According to these data, significant variations in these relevant factors are likely to occur between different locations within a Tumor, and between Tumors of the same grade and clinical stage. The extent and mechanisms by which the microenvironmental factors influence cellular response to standard irradiation, chemotherapeutic drugs, immunotherapy and localized hyperthermia are described and "physiological" barriers to treatment are outlined.
-
Do Changes in Tumor Blood Flow Necessarily Lead to Changes in Tissue Oxygenation and in Bioenergetic Status
Advances in experimental medicine and biology, 1994Co-Authors: Peter Vaupel, Debra K. Kelleher, T. EngelAbstract:An increasing number of investigations carried out in recent years provide evidence suggesting that “chronic” decreases in Tumor Blood Flow and/or tissue oxygenation (e.g., during Tumor growth) or acute declines in the tissue perfusion (e.g., following therapeutic measures) might be accompanied by significant reductions in the energy status. In several instances, positive correlations between energy status and Tumor Blood Flow or oxygenation have been reported (Lilly et al., 1985; Evelhoch et al., 1986; Tozer et al., 1989; Vaupel et al., 1989a, 1989b; Steen and Graham, 1991), and these investigations have led to the conclusion that Blood Flow may be the limiting factor in determining the bioenergetic status of Tumors during growth. Manipulations of Tumor Blood Flow by vasodilators, hyperthermia, Tumor necrosis factor-α (TNF-α), lymphotoxin, interleukin-1, x-irradiation or after i.p. mannitol administration were accompanied by parallel changes in Tumor energy status. Only in studies where i.p. or i.v. glucose was administered was energy status found to be stable or even slightly improved despite significant reductions in Tumor perfusion (Okunieff et al., 1989; Kruger et al., 1991; Mayer et al., 1992; Schaefer et al., 1993). Similar observations of a dissociation between changes in Tumor Blood Flow, oxygenation and energetic status have been observed in normoglycemic mice during photodynamic therapy (Bremner et al., 1993) or following hydralazine administration in xenografted human and isotransplanted murine Tumors (Bremner et al., 1991; Adams et al., 1992).
-
Measurements of Tumor Blood Flow using intraperitoneal deuterium and 2H-NMR spectroscopy.
Advances in experimental medicine and biology, 1992Co-Authors: Paul Okunieff, Junhee Lee, Masamitsu Itoh, Peter VaupelAbstract:Tumors usually have a sparse, disorganized, and inefficient vascular network that leaves a large fraction of the Tumor cells in an oxygen deprived and hostile metabolic microenvironment. Hence Tumor Blood Flow, or more correctly nutritive perfusion, has important interactions with treatment efficacy. For example, hypoxic Tumor cells, which occur in Tumors with low Blood Flow, are less susceptible to radiation and are probably responsible for most radiation treatment failures (Adams, 1981). Similarly, cytotoxic drug delivery could be predicted by Blood Flow measurements, with clear implications regarding the expected success of chemotherapy. Thus, the ability to conveniently measure Tumor Blood Flow would have considerable clinical utility. This report describes a new, simple method of using deuterium nuclear magnetic resonance spectroscopy (NMR) to determine Tumor Blood Flow.
-
Measurement of human Tumor Blood Flow: a positron technique using an artifact of high energy radiation therapy.
Advances in experimental medicine and biology, 1992Co-Authors: Paul Okunieff, Junhee Lee, Peter VaupelAbstract:For at least three decades (1–6) there has been an interest in measuring Tumor Blood Flow (TBF) and in the determination of its relation to the response of human Tumors to radiation, drug therapies, and to the probability of development of distant metastases. The proton activation method which will be described below allows daily measurements of Blood Flow, in only 7 minutes, in patients being irradiated by photons of ≥20 MV, or by protons and other heavy particles.
Jørgen Frøkiær - One of the best experts on this subject based on the ideXlab platform.
-
repeatability of Tumor Blood Flow quantification with 82 rubidium pet ct in prostate cancer a test retest study
EJNMMI research, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Katrine Bodkergaard Nielsen, Jens Nørkær SørensenAbstract:Non-invasive Tumor Blood Flow (TBF) quantification is a candidate approach for risk stratification and monitoring of prostate cancer patients. Validation data have recently been published on prostate TBF measurement with the widely used positron emission tomography (PET) Flow tracer 82Rubidium (82Rb). However, no test-retest data is available for TBF measurement with 82Rb PET in prostate cancer. Such information is important to determine the potential clinical usefulness of the technique. The aim of the present study was to determine the test-retest repeatability of TBF measurement with both dynamic and static 82Rb PET. We recruited 10 low-to-high-risk prostate cancer patients scheduled for clinical prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) or magnetic resonance imaging. Pelvic and cardiac static and dynamic 82Rb PET/CT were performed at baseline and repeated on a different day within 1 week. In total, 11 primary lesions were analyzed. For K1, standardized uptake values (SUV)max, SUVmean, and SUVpeak, prostate cancer 82Rb PET TBF has a repeatability of 32%, 51%, 53%, and 58% and an intraclass correlation of 0.98, 0.89, 0.88, and 0.88, respectively. Dynamic 82Rb PET/CT with kinetic modeling measures TBF in prostate cancer with high repeatability, which allows identification of Blood Flow changes of 32%. Static late-uptake 82Rb PET/CT is inferior, and only intra-individual Blood Flow changes above 51% can hence be recognized.
-
Test-retest study of Tumor Blood Flow quantification with 82Rubidium-PET/CT in prostate cancer
The Journal of Nuclear Medicine, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Jens Nørkær Sørensen, Lars Poulsen TolbodAbstract:1556 Objectives: Non-invasive quantification of Tumor Blood Flow (TBF) is a potential method for risk-stratification and monitoring in prostate cancer. We have recently validated 82Rubidium (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer. However, no test-retest data exist on prostate TBF measurement with 82Rb PET. This information is crucial to determine the potential clinical impact of this method. The aim of this study was to determine the reproducibility of 82Rb PET for TBF measurement. Methods: Ten low-risk to high-risk prostate cancer patients were recruited in connection with clinical prostate specific membrane antigen (PSMA) PET/ computed tomography (CT) or magnetic resonance imaging (MRI). Static 82Rb PET/CT scans were performed of the pelvic region and retest scans were performed on a different day, within one week of the baseline scan. Since the variance of the differences depend on the mean, the analyses were performed on log-transformed data to avoid this bias. Results: TBF with 82Rb PET can be measured in prostate Tumors with an intraclass correlation of (0.89; 0.88 and 0,88); a within-subject coefficient of variance of (18.3 %; 18.9 % and 21.0 %); and a repeatability coefficient of (50.8 %; 52.3 % and 58.3 %) for SUVmax, SUVmean and SUVpeak respectively. Conclusions: TBF measured using static 82Rb PET/CT in prostate cancer can be reproduced with a coefficient of variance and repeatability of approximately 20% and 55%, respectively, depending on SUV measure. Consequently, the method can be applied to monitor relative changes in TBF above 55% in serial exams. Financial support This work was financially supported by The Danish Cancer Society, Health Research Fund of Central Denmark Region, P. Carl Petersens Fond, Dansk Kraeftforskningsfond and Knud og Edith Eriksens Mindefond.
-
test retest study of Tumor Blood Flow quantification with 82rubidium pet ct in prostate cancer
The Journal of Nuclear Medicine, 2019Co-Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche, Michael Borre, Jørgen Frøkiær, Jens Nørkær SørensenAbstract:1556 Objectives: Non-invasive quantification of Tumor Blood Flow (TBF) is a potential method for risk-stratification and monitoring in prostate cancer. We have recently validated 82Rubidium (82Rb) positron emission tomography (PET) for TBF measurement in prostate cancer. However, no test-retest data exist on prostate TBF measurement with 82Rb PET. This information is crucial to determine the potential clinical impact of this method. The aim of this study was to determine the reproducibility of 82Rb PET for TBF measurement. Methods: Ten low-risk to high-risk prostate cancer patients were recruited in connection with clinical prostate specific membrane antigen (PSMA) PET/ computed tomography (CT) or magnetic resonance imaging (MRI). Static 82Rb PET/CT scans were performed of the pelvic region and retest scans were performed on a different day, within one week of the baseline scan. Since the variance of the differences depend on the mean, the analyses were performed on log-transformed data to avoid this bias. Results: TBF with 82Rb PET can be measured in prostate Tumors with an intraclass correlation of (0.89; 0.88 and 0,88); a within-subject coefficient of variance of (18.3 %; 18.9 % and 21.0 %); and a repeatability coefficient of (50.8 %; 52.3 % and 58.3 %) for SUVmax, SUVmean and SUVpeak respectively. Conclusions: TBF measured using static 82Rb PET/CT in prostate cancer can be reproduced with a coefficient of variance and repeatability of approximately 20% and 55%, respectively, depending on SUV measure. Consequently, the method can be applied to monitor relative changes in TBF above 55% in serial exams. Financial support This work was financially supported by The Danish Cancer Society, Health Research Fund of Central Denmark Region, P. Carl Petersens Fond, Dansk Kraeftforskningsfond and Knud og Edith Eriksens Mindefond.
